Vistagen Therapeutics (VTGN) Stock Price, Quote, News & History

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

$4.38

$4.36

Volume / Avg.

603.75K / 707.51K

Day Range

$4.30 - $4.50

52 Wk Range

1.90 - 5.14

Market Cap

$174.57M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

4.61%

Days to Cover

1.14

Recent Vistagen Therapeutics Inc News

All You Need to Know About VistaGen Therapeutics Rating Upgrade to Buy

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

Zacks

Undervalued VistaGen Therapeutics, Analyst Highlights Potential In Anxiety Treatment

William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety disorder (SAD) and other

Vandana Singh

Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst

Analysts at Stifel recently initiated coverage on Vistagen Therapeutics Inc (NASDAQ: VTGN), emphasizing the potential of its lead asset, fasedienol, in clinical development for social anxiety disorder (SAD).

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Key Statistics

Open

$4.38

$4.36

Volume / Avg.

603.75K / 707.51K

Day Range

$4.30 - $4.50

52 Wk Range

1.90 - 5.14

Market Cap

$174.57M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

4.61%

Days to Cover

1.14

About

Sector

Health Care

Industry

Biotechnology

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neur...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry